Yasaman Rahimi

Yasaman Rahimi

Auto-generated profile, based on publicly available information

Yasaman Rahimi

University of Maryland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
IVIman Elahi Vahed
Iman Elahi Vahed
YRYasaman Rahimi
Yasaman Rahimi
SKShima Karbasi
Shima Karbasi
ASali safdari
ali safdari
MRMohammad Rahmanian
Mohammad Rahmanian
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a persistent hepatic condition linked with cardiovascular disorders and metabolic disturbances. Characterized by inflammation, fat accumulation, and fibrosis within the liver, MASLD can develop into liver cancer and cirrhosis. With a global prevalence of 32.4%, the condition parallels rising obesity rates. Orlistat inhibits lipase enzymes and, therefore, reduces dietary fat absorption, which may benefit MASLD patients. The present systematic review and meta-analysis were performed in accordance with PRISMA guidelines. Searches of PubMed, Scopus, Web of Science, and Embase up to January 2025 were performed using specific keywords and MeSH terms. Bias assessment and data extraction were conducted using Joanna Briggs Institute (JBI) tools independently by two researchers. Statistical analyses were performed with Stata version 14, calculating standardized mean differences, 95% confidence intervals (CI), and heterogeneity (by performing Cochran’s Q test and I² index). Moreover, metaregression, subgroup analyses, and sensitivity analyses were conducted. Eleven studies featuring 582 participants were included. Orlistat treatment induced a significant reduction in levels of alanine transaminase (ALT) (SMD = -26.23; 95% CI = -34.70 to -17.76) and aspartate aminotransferase (AST) (SMD = -19.62; 95% CI = -28.33 to -10.92). Furthermore, reductions in HOMA-IR, body mass index,cholesterol, insulin, and waist circumference were observed. The included studies exhibited low to moderate heterogeneity for most outcomes, indicating consistent results across trials. Orlistat significantly improved AST, ALT, and some other metabolic parameters in MASLD patients, suggest-ing its potential as an additional treatment option. However, the outcome must be interpreted cautiously, considering study heterogeneity. Further high-quality, multicenter research is necessary to confirm these results.

17 June 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
AVAjith Vemuri
Ajith Vemuri
YRYasaman Rahimi
Yasaman Rahimi
ASAlireza Vafaei Sadr
Alireza Vafaei Sadr
SHsina hejazian
sina hejazian
Shouhao ZhouShouhao Zhou
Shouhao Zhou
Ramin ZandRamin Zand
Ramin Zand
Background: Lack of physical activity is a major risk factor for cardiovascular diseases. Wearables and smartphones offer potential advantages in cost, accessibility, and scale to change physical activity. This systematic review aims to determine if interventions comprising smartphones and wearables are effective in enhancing physical activity among individuals with cardiovascular disease. Methods: PubMed, Cochrane, and Web of Science databases were searched for randomized controlled trials, published since January 2000, on wearables and smartphone applications to enhance physical activity among patients with cardiovascular disease. Nonrandomized trials and interventions without a smartphone/wearable component were excluded. Risk of bias was assessed by the Cochrane Collaboration tool. Meta‐analyses were performed to assess the pooled effect on steps per day, distance, oxygen consumption, and (moderate‐to‐vigorous) physical activity in minutes per day. Results: Fourteen randomized controlled trials were included. Interventions comprising smartphones and wearables resulted in a mean difference of 1097.4 (95% CI, 409.2–1785.6; P =0.0018) steps per day, and 3.9 (95% CI, 0.2–7.6; P =0.0413) minutes of moderate‐vigorous physical activity per day compared with control groups. Conclusion: This meta‐analysis showed that interventions comprising smartphones and wearable devices are effective at increasing physical activity among patients with cardiovascular disease. Wearables and smartphones could provide accessible and tailored interventions to enhance physical activity.